← all works
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Field
- Medicine
- Canadian institutions
- University of TorontoSt. Michael's HospitalCentre Hospitalier de l’Université de Montréal
- Funders
- —
- Keywords
- AcarboseMedicineImpaired glucose tolerancePlaceboInternal medicineDiabetes mellitusFlatulenceType 2 diabetesClinical endpointType 2 Diabetes MellitusGastroenterologyHazard ratioRandomized controlled trialEndocrinologyConfidence intervalPathology
- Has abstract in OpenAlex
- no